[1]章靖源,周恩超.血管内皮生长因子靶向药相关性蛋白尿发病机制和中医药治疗研究进展[J].陕西中医,2023,(5):667-669.[doi:DOI:10.3969/j.issn.1000-7369.2023.05.031]
　ZHANG Jingyuan,ZHOU Enchao.Research progress on mechanism of VEGF targeted drug-related proteinuria and treatment of traditional Chinese medicine[J].,2023,(5):667-669.[doi:DOI:10.3969/j.issn.1000-7369.2023.05.031]
点击复制

血管内皮生长因子靶向药相关性蛋白尿发病机制和中医药治疗研究进展
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2023年5期
页码:
667-669
栏目:
综 述
出版日期:
2023-05-05

文章信息/Info

Title:
Research progress on mechanism of VEGF targeted drug-related proteinuria and treatment of traditional Chinese medicine
作者:
章靖源; 周恩超
(南京中医药大学附属医院,江苏 南京 210029)
Author(s):
ZHANG Jingyuan; ZHOU Enchao
(Affiliated Hospital of Nanjing University of Chinese Medicine,Nanjing 210029,China)
关键词:
血管内皮生长因子靶向药;  蛋白尿;  肾小球血栓性微血管病;  微小病变性肾病;  局灶节段性肾小球硬化
Keywords:
VEGF targeted drugs;  Proteinuria;  Glomerular thrombotic microangiopathy;  Minimal change nephropathy;  Focal segmental glomerulosclerosis
分类号:
R 696.2
DOI:
DOI:10.3969/j.issn.1000-7369.2023.05.031
文献标志码:
A
摘要:
血管内皮生长因子(VEGF)靶向药目前越来越多地应用于恶性肿瘤的临床治疗,安全有效,易耐受,但仍会产生蛋白尿等常见的不良反应。VEGF靶向药相关性蛋白尿的发病机制主要是足细胞和内皮细胞改变及血管内皮细胞功能障碍。西医对症处理多有局限性,效果不显著。中医药辨治可有效改善VEGF靶向药所致的蛋白尿,提高临床疗效,改善患者生活质量,延长生存期。今后需进一步加强中医药防治VEGF靶向药相关性蛋白尿的机制研究,开展大样本、高质量的临床试验研究,为临床提供更多的参考。
Abstract:
VEGF targeted drugs are increasingly used in the clinical treatment of malignant tumors.They are safe,effective and easily tolerated,but they will still produce common adverse reactions such as proteinuria.The mechanism of VEGF targeted drug-related proteinuria is mainly the changes of podocytes and endothelial cells and the dysfunction of vascular endothelial cells.Western medicine has many limitations in symptomatic treatment,and the effect is not significant.TCM syndrome differentiation and treatment can effectively improve the proteinuria caused by VEGF targeted drugs,improve the clinical curative effect,improve the quality of life of patients and prolong the survival time.In the future,it is necessary to further strengthen the mechanism research of traditional Chinese medicine in the prevention and treatment of VEGF targeted drug-related proteinuria,and carry out large sample and high-quality clinical trial research,so as to provide more references for clinical practice.

参考文献/References:

[1] Lovet JM,Montal R,Sia D,et al.Molecular therapies and precision medicine for hepatocellular carcinoma[J].Nature Reviews Clinical Oncology,2018,15(10):599-616.
[2] 贺春艳,吴月明.非小细胞肺癌患者缺氧诱导因子、血管内皮细胞生长因子表达水平及其临床意义[J].陕西医学杂志,2022,51(4):503-506.
[3] Homsi J,Daud AI.Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors[J].Cancer Control,2007,14(3):285-294.
[4] Soria JC,Massard C,Izzedine H.From theoretical synergy to clinical supra-additive toxicity[J].J Clin Oncology,2009,27(9):1359-1361.
[5] Bartlett CS,Jeansson M, Quaggin SE.Vascular growth factors and glomerular disease[J].Annu Rev Physiol,2016,78:437-461.
[6] Foster RR.The importance of cellular VEGF bioactivity in the development of glomerular disease[J].Nephron Exp Nephrol,2009,113(1):e8-e15.
[7] Sugimoto H,Hamano Y,Charytan D,et al.Neutralization of circulating vascular endothelial growth factor(VEGF)by anti-VEGF antibodies and soluble VEGF receptor 1(sFlt-1)induces proteinuria[J].J Biol Chem,2003,278(15):12605-12608.
[8] Meiracker AH.Mechanisms of hypertension and renal injury during vascular endothelial growth factor signaling inhibition[J].Hypertension,2016,68(1):17-23.
[9] Siragusa M,Fleming I.The eNOS signalosome and its link to endothelial dysfunction[J].Pflugers Arch,2016,468(7):1125-1137.
[10] Eremina V,Jefferson JA,Kowalewska J,et al.VEGF inhibition and renal thrombotic miemangiopathy[J].N Engl J Med,2008,358(11):1129-1136.
[11] Izzedine H,Escudier B,Lhomme C,et al.Kidney diseases associated with anti-vascular endothelial growth factor(VEGF):An 8-year observational study at a single center[J].Medicine,2014,93(24):333-339.
[12] Izzedine H,Mangier M,Ory V,et al.Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy[J].Kidney Int,2014,85(2):457-470.
[13] Bertelli R,Bonanni A,Caridi G,et al.Molecular and cellular mechanisms for proteinuria in minimal change disease[J].FrontMed(Lausanne),2018,5:170.
[14] New LA,Martin CE,Scott RP,et al.Nephrin tyrosine phosphorylation is required to stabilize and restore podocyte foot process architecture[J].J Am Soc Nephrol,2016,27(8):2422-2435.
[15] Sendeyo K,Audard V,Zhang SY.Upregulation of c-mip is closely related to podocyte dysfunction in membranous nephropathy[J].Kidney Int,2013,83(3):414-425.
[16] 叶知锋,黄 挺,何飞燕,等.益肾健脾固精汤联合厄贝沙坦治疗VEGF信号通路抑制剂相关蛋白尿的疗效观察[J].中国中医药科技,2019,26(2):204-206.
[17] 许林利,查名宝.2例阿帕替尼致蛋白尿的中医辨证治疗[J].皖南医学院学报,2016,35(6):611-612.
[18] 丁美钱,梁 惠,吴厚海,等.调胃和血汤联合阿帕替尼治疗晚期胃癌的临床观察[J].中国中西医结合杂志,2018,38(12):1440-1443.
[19] 刘春秋,李国欢,张 静,等.清热利湿法预防阿帕替尼引起的蛋白尿的临床研究[J].中国医药导刊,2019,21(12):723-726.
[20] 肖 康.扶正消浊汤联合厄贝沙坦治疗阿帕替尼所致气阴两虚湿浊瘀阻型蛋白尿的临床研究[D].合肥:安徽中医药大学,2019.
[21] 赵梓萱.加减肾气丸干预胃癌阿帕替尼靶向治疗相关性蛋白尿的临床观察[D].成都:成都中医药大学,2021.
[22] 陈 玲,黄 挺.黄挺教授辨证治疗舒尼替尼相关蛋白尿的经验[J].浙江中医药大学学报,2018,42(5):377-379.
[23] 徐建林,顾银霞.活血化瘀法早期干预贝伐珠单抗所致肿瘤患者高血压及蛋白尿的研究[J].中国肿瘤临床与康复,2022,29(2):151-153.
[24] 孙怡婕,黄春锦,韩 力,等.益肾化浊法联合洛汀新治疗贝伐珠单抗诱发老年晚期结直肠癌患者蛋白尿肾虚兼湿浊证的临床观察[J].老年医学与保健,2021,27(4):818-822,833.
[25] 陈 笑.五倍子治疗贝伐珠单抗所致蛋白尿的临床疗效观察[D].南京:南京中医药大学,2019.
[26] 陈小蕾.五倍子治疗蛋白尿的研究[J].中国民间疗法,2017,15(4):92-93.
[27] 阎 佳,张学玉,刘 锐.金水宝胶囊临床应用和药理作用的研究进展[J].中国临床药理学杂志,2019,35(4):406-408.
[28] 梁 衍,张琳萍.黄葵胶囊联合氯沙坦钾治疗IgA肾病临床观察[J].陕西中医,2017,38(9):1192-1193.
[29] 冯 强,李保华.昆仙胶囊治疗蛋白尿的研究进展[J].新疆中医药,2020,38(2):93-96.
[30] 张 敏,杨江生.肾炎康复片配合西药治疗慢性肾脏病蛋白尿疗效观察[J].陕西中医,2015,36(4):387-390.

相似文献/References:

[1]王晓强,于佳佳,王晓雷△,等.从“升降出入”理论探讨糖尿病肾病蛋白尿治法[J].陕西中医,2020,(3):368.
[2]张 舒,阮 园,周静波,等.芪葵颗粒治疗糖尿病肾病疗效及对患者尿结缔组织生长因子和血清sICAM-1的影响[J].陕西中医,2021,(3):308.[doi:DOI:10.3969/j.issn.1000-7369.2020.03.009]
　ZHANG Shu,RUAN Yuan,ZHOU Jingbo,et al.Effect of Qikui particles on diabetic kidney disease and its influence on urinary CTGF and serum sICAM-1[J].,2021,(5):308.[doi:DOI:10.3969/j.issn.1000-7369.2020.03.009]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目(81873270); 江苏省“六大人才高峰”高层次人才项目(WSN-012); 南京市科技局医疗卫生国际联合研发项目(202002051); 南京中医药大学中医学优势学科三期项目(ZYX03KF076)
更新日期/Last Update: 2023-05-09